Pi3k
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Pi3k is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Targeting the PI3K/AKT/mTOR pathway in gastrointestinal cancers: a comprehensive review of mechanisms, preclinical evidence, and clinical challenges. · Med Oncol · 2026-08-29
- Potential multi-target inhibition of the PI3K-Akt pathway by Fraxetin suppresses colorectal cancer and restores 5-FU sensitivity in 5-FU-resistant CRC cells: An integrated study combining network pharmacology, molecular simulation, and in vitro validation. · Biochem Biophys Res Commun · 2026-08-20
- IGF2BP3-Mediated m6A Modification of OLR1 mRNA Promotes Immune Evasion in CRC via the PI3K/AKT/mTOR Pathway. · J Immunother · 2026-08-13
- FGFR2 mediates the progression of colorectal cancer by promoting the expression of HIF-1α via the PI3K/AKT/mTOR pathway. · Tissue Cell · 2026-08-06
- Integrated network pharmacology, molecular docking, and experimental validation reveal synergistic inhibition of EGFR and PI3K-Akt/JAK2-STAT3 pathways by Esculin and Esculetin to exert anti-colorectal cancer effects. · Toxicol Appl Pharmacol · 2026-08-04
- DEC1 mediates IL-6-induced EMT in CRC via PI3K/AKT/NF-κB activation. · J Biomed Res · 2026-07-25
What the reporting says
It shows up alongside Colorectal Cancer (17), KRAS (8).
Two steps out: Braf (through Colorectal Cancer, 17 shared stories on the weaker link); Chen (through Colorectal Cancer, 17 shared stories on the weaker link); ctDNA (through Colorectal Cancer, 17 shared stories on the weaker link); Egfr (through Colorectal Cancer, 17 shared stories on the weaker link).
Tracked since Mar 5, with coverage on 20 separate days — concentrated in Pubmed Targeted and Oncology.